Nifuratel

Antibacterial, antifungal, and antiprotozoal compound CAS# 4936-47-4

Nifuratel

Catalog No. BCC1800----Order now to get a substantial discount!

Product Name & Size Price Stock
Nifuratel: 5mg $92 In Stock
Nifuratel: 10mg Please Inquire In Stock
Nifuratel: 20mg Please Inquire Please Inquire
Nifuratel: 50mg Please Inquire Please Inquire
Nifuratel: 100mg Please Inquire Please Inquire
Nifuratel: 200mg Please Inquire Please Inquire
Nifuratel: 500mg Please Inquire Please Inquire
Nifuratel: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Nifuratel

Number of papers citing our products

Chemical structure

Nifuratel

3D structure

Chemical Properties of Nifuratel

Cas No. 4936-47-4 SDF Download SDF
PubChem ID 6507267 Appearance Powder
Formula C10H11N3O5S M.Wt 285.28
Type of Compound N/A Storage Desiccate at -20°C
Synonyms NF 113; SAP 113; Methylmercadone
Solubility DMSO : 50 mg/mL (175.27 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name 5-(methylsulfanylmethyl)-3-[(Z)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
SMILES CSCC1CN(C(=O)O1)N=CC2=CC=C(O2)[N+](=O)[O-]
Standard InChIKey SRQKTCXJCCHINN-WCIBSUBMSA-N
Standard InChI InChI=1S/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3/b11-4-
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Nifuratel

DescriptionNifuratel(NF 113, SAP 113) is a broad antibacterial spectrum agent, which is used as an antibacterial, antifungal, and antiprotozoal (Trichomonas). IC50 Value: 0.125-1 μg/mL(MIC, A. vaginae) [1] Target: Antibacterial; Antiprotozoal in vitro: In vitro, nifuratel is able to inhibit the growth of A. vaginae, with a MIC range of 0.125-1 μg/mL; it is active against G. vaginalis and does not affect lactobacilli [1]. in vivo: Patients were randomized to receive a 2-week course of bismuth subcitrate (8 mg/kg/day, q.d.s.), amoxicillin (50 mg/kg/day, q.d.s.), with either nifuratel (15 mg/kg/day, q.d.s.) or furazolidone (10 mg/kg/day, q.d.s.), plus omeprazole (0.5 mg/kg, once daily) [2]. Toxicity: There were no serious adverse reactions and were no withdrawals due to any side-effects. All of side-effects were self-limiting (dark stools, urine discoloration, blackening of the tongue, and others) [3]. Clinical trial: N/A

References:
[1]. Polatti F. Bacterial vaginosis, Atopobium vaginae and nifuratel. Curr Clin Pharmacol. 2012 Feb 1;7(1):36-40. [2]. Nijevitch AA, et al. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy withnifuratel to furazolidone. Aliment Pharmacol Ther. 2005 Nov 1;22(9):881-7. [3]. Nijevitch AA, et al. Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children. Helicobacter. 2007 Apr;12(2):132-5.

Nifuratel Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Nifuratel Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Nifuratel

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.5053 mL 17.5266 mL 35.0533 mL 70.1066 mL 87.6332 mL
5 mM 0.7011 mL 3.5053 mL 7.0107 mL 14.0213 mL 17.5266 mL
10 mM 0.3505 mL 1.7527 mL 3.5053 mL 7.0107 mL 8.7633 mL
50 mM 0.0701 mL 0.3505 mL 0.7011 mL 1.4021 mL 1.7527 mL
100 mM 0.0351 mL 0.1753 mL 0.3505 mL 0.7011 mL 0.8763 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Nifuratel

Description: IC50 Value: 0.125-1 μg/mL(MIC, A. vaginae) [1] Nifuratel appears to have a broad antibacterial spectrum of action and is effective against Chlamydia trachomatis and Mycoplasma spp. as well as fungal infections from Candida spp. in vitro: In vitro, nifuratel is able to inhibit the growth of A. vaginae, with a MIC range of 0.125-1 μg/mL; it is active against G. vaginalis and does not affect lactobacilli [1]. in vivo: Patients were randomized to receive a 2-week course of bismuth subcitrate (8 mg/kg/day, q.d.s.), amoxicillin (50 mg/kg/day, q.d.s.), with either nifuratel (15 mg/kg/day, q.d.s.) or furazolidone (10 mg/kg/day, q.d.s.), plus omeprazole (0.5 mg/kg, once daily) [2]. Toxicity: There were no serious adverse reactions and were no withdrawals due to any side-effects. All of side-effects were self-limiting (dark stools, urine discoloration, blackening of the tongue, and others) [3]. Clinical trial: N/A

Featured Products
New Products
 

References on Nifuratel

Bacterial vaginosis, Atopobium vaginae and nifuratel.[Pubmed:22082330]

Curr Clin Pharmacol. 2012 Feb 1;7(1):36-40.

As bacterial vaginosis (BV) is a potential cause of obstetric complications and gynecological disorders, there is substantial interest in establishing the most effective treatment. Standard treatment - metronidazole or clindamycin, by either vaginal or oral route is followed by relapses in about 30% of cases, within a month from treatment completion. This inability to prevent recurrences reflects our lack of knowledge on the origins of BV. Atopobium vaginae has been recently reported to be associated with BV in around 80% of the cases and might be involved in the therapeutic failures. This review looks at the potential benefits of Nifuratel against A. vaginae compared to the standard treatments with metronidazole and clindamycin. In vitro, Nifuratel is able to inhibit the growth of A. vaginae, with a MIC range of 0.125-1 mug/mL; it is active against G. vaginalis and does not affect lactobacilli. Metronidazole is active against A. vaginae only at very high concentrations (8-256 mug/mL); it is partially active against G. vaginalis and also has no effect on lactobacilli. Clindamycin acts against A. vaginae with an MIC lower than 0.125 mug/mL and is active on G. vaginalis but it also affects lactobacilli, altering the vaginal environment. These observations suggest that Nifuratel is probably the most valid therapeutic agent for BV treatment.

In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis?[Pubmed:21321147]

Antimicrob Agents Chemother. 2011 May;55(5):2490-2.

Bacterial vaginosis is characterized by a shift of the physiological flora to a diverse spectrum of bacteria, where Gardnerella vaginalis and Atopobium vaginae are the most important markers. In this study, the antimicrobial activity of Nifuratel against G. vaginalis, A. vaginae, and lactobacilli was compared with that of the two currently used antibiotics metronidazole and clindamycin. Results suggest that Nifuratel has a better spectrum of activity, being highly active against G. vaginalis and A. vaginae without affecting lactobacilli.

High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort study.[Pubmed:27435791]

J Obstet Gynaecol Res. 2016 Oct;42(10):1354-1360.

AIM: The efficacy and safety of two Nifuratel dosages for the treatment of aerobic vaginitis (AV) were compared. METHODS: This was a prospective open-label cohort study of patients diagnosed and treated at the Tianjin Third Central Hospital between January 2012 and December 2013. The co-presence of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), or/and trichomonal vaginitis (TV; mixed AV) was determined. Patients were randomized to Nifuratel-500 (500 mg Nifuratel, intravaginal, 10 days) or Nifuratel-250 (250 mg Nifuratel, intravaginal, 10 days), and followed-up for three to seven days after treatment completion. Primary and secondary outcomes were recovery rate and adverse events, respectively. RESULTS: The study included 142 patients with AV. Age was not significantly different between the groups (n = 71 each), and disease distribution was identical: 29 (40.85%) simple AV and 42 (59.15%) mixed AV (AV + BV, 42.86 %; AV + VVC, 30.95%; AV + TV, 26.19%). In patients with simple AV, the recovery rate did not differ significantly between the Nifuratel-500 (26/29, 89.66%) and Nifuratel-250 (22/29, 75.86%) groups. In patients with mixed AV, recovery rates were significantly higher in the Nifuratel-500 than in the Nifuratel-250 group (AV + BV, 88.89% vs 50.00 %; AV + VVC, 76.92 % vs 30.77 %; AV + TV, 90.91 % vs 36.36%; all P < 0.05). Only one patient (Nifuratel-500) reported an adverse event (mild anaphylactic reaction). CONCLUSION: Nifuratel 500 mg showed good clinical efficacy for the treatment of AV, particularly mixed AV, and is superior to the 250 mg dosage in the treatment of mixed AV.

Description

Nifuratel(NF 113, SAP 113) is a broad antibacterial spectrum agent, which is used as an antibacterial, antifungal, and antiprotozoal (Trichomonas).

Keywords:

Nifuratel,4936-47-4,NF 113; SAP 113; Methylmercadone,Natural Products,Antibiotic, buy Nifuratel , Nifuratel supplier , purchase Nifuratel , Nifuratel cost , Nifuratel manufacturer , order Nifuratel , high purity Nifuratel

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: